Heike Richly
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Melero I, de Miguel Luken M, de Velasco G, Garralda E, Martin-Liberal J, Jörger M, Alonso G, Goebeler M, Schuler M, König D, Dummer R, Reig M, Rodriguez Ruiz M, Calvo E, Esteban-Villarrubia J, Oberoi A, Sabat P, Soto-Castillo J, Koster K, Saavedra O, Sayehli C, Gromke T, Läubli H, Ramelyte E, Fortuny M, Landa-Magdalena A, Moreno I, Torres-Jiménez J, Hernando-Calvo A, Hess D, Racca F, Richly H, Schmitt A, Eggenschwiler C, Sanduzzi-Zamparelli M, Vilalta-Lacarra A, Trojan J, Koch C, Galle P, Foerster F, Trajanoski Z, Hackl H, Gogolla F, Koll F, Wild P, Chun F, Reis H, Lloyd P, Machacek M, Gajewski T, Fridman W, Eggermont A, Bargou R, Schöniger S, Rüschoff J, Tereshchenko A, Zink C, Dantas-Silva A, Lichtenegger F, Akdemir J, Rüdiger M, L'Huillier P, Dutta A, Haake M, Auckenthaler A, Gjorgjioska A, Rössler B, Hermann F, Liebig M, Reichhardt D, Schuberth-Wagner C, Wischhusen J, Fettes P, Auer M, Klar K, Leo E. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 2024
Dec 11, 2024Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.
Dec 11, 2024Nature 2024
Melero Ignacio, de Miguel Luken Maria, de Velasco Guillermo, Garralda Elena, Martin-Liberal Juan, Jörger Markus, Alonso Guzman, Goebeler Maria-Elisabeth, Schuler Martin, König David, Dummer Reinhard, Reig Maria, Rodriguez Ruiz Maria-Esperanza, Calvo Emiliano, Esteban-Villarrubia Jorge, Oberoi Arjun, Sabat Paula, Soto-Castillo Juan José, Koster Kira-Lee, Saavedra Omar, Sayehli Cyrus Michael, Gromke Tanja, Läubli Heinz, Ramelyte Egle, Fortuny Marta, Landa-Magdalena Ana, Moreno Irene, Torres-Jiménez Javier, Hernando-Calvo Alberto, Hess Dagmar, Racca Fabricio, Richly Heike, Schmitt Andreas Michael, Eggenschwiler Corinne, Sanduzzi-Zamparelli Marco, Vilalta-Lacarra Anna, Trojan Jörg, Koch Christine, Galle Peter R, Foerster Friedrich, Trajanoski Zlatko, Hackl Hubert, Gogolla Falk, Koll Florestan J, Wild Peter J, Chun Felix Kyoung Hwan, Reis Henning, Lloyd Peter, Machacek Matthias, Gajewski Thomas F, Fridman Wolf H, Eggermont Alexander M M, Bargou Ralf C, Schöniger Sandra, Rüschoff Josef, Tereshchenko Anastasiia, Zink Carina, Dantas-Silva Amanda, Lichtenegger Felix S, Akdemir Julia, Rüdiger Manfred, L'Huillier Phil, Dutta Aradhana, Haake Markus, Auckenthaler Alexandra, Gjorgjioska Ana, Rössler Bernhard, Hermann Frank, Liebig Mara, Reichhardt Daniela, Schuberth-Wagner Christine, Wischhusen Jörg, Fettes Petra, Auer Marlene, Klar Kathrin, Leo Eugen
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Schuler M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Schostak M, Park S, Cho B, Sayehli C, Navarro A, Soo R, Richly H, Cassier P, Tai D, Penel N, Nogova L, Jörger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019
Aug 9, 2019Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study
Aug 9, 2019Lancet Oncol 2019
Schuler Martin, Gajate Pablo, Cathomas Richard, Rajagopalan Prabhu, Grevel Joachim, Bender Sebastian, Boix Oliver, Nogai Hendrik, Ocker Matthias, Ellinghaus Peter, Schostak Martin, Park Se Hoon, Cho Byoung Chul, Sayehli Cyrus Michael, Navarro Alejandro, Soo Ross A, Richly Heike, Cassier Philippe Alexandre, Tai David, Penel Nicolas, Nogova Lucia, Jörger Markus